1. Hemoglobin, EPO, & Iron dose figure 4
Hemoglobin, EPO, & Iron dose figure 4.1 period prevalent hemodialysis patients

2. Mean monthly hemoglobin at initiation of therapy & in the first 6 months of ESRD figure 4.2, incident hemodialysis patients

3. Mean EPO dose per week after initiation of & in the first 6 months of ESRD figure 4.3, incident hemodialysis patients

4. Percent of patients receiving iron at initiation of therapy & in the first 6 months of ESRD figure 4.4, incident hemodialysis patients

5. Mean monthly hemoglobin by initial Hb from the ME form figure 4
Mean monthly hemoglobin by initial Hb from the ME form figure 4.5, incident dialysis patients, combined

6. Mean EPO dose per week by initial Hb from the ME form figure 4
Mean EPO dose per week by initial Hb from the ME form figure 4.6, incident dialysis patients, combined

7. Percentage of patients receiving iv iron by initial Hb from the ME form figure 4.7, incident dialysis patients, combined

8. Prevalent patient counts, by data source table 4
Prevalent patient counts, by data source table 4.a, point prevalent ESRD patients; only patients with data in both databases

9. Prevalent patient counts, by data source table 4
Prevalent patient counts, by data source table 4.a, point prevalent ESRD patients; only patients with data in both databases (cont.)

10. Trends in mean hemoglobin, by modality, iron use, data source, & EPO use figure 4.8

11. Trends in mean hemoglobin, by modality, iron use, data source, & EPO use figure 4.8 (cont.)

12. Trends in mean EPO dose per week, by modality, iron use, & data source figure 4.9

13. Trends in mean EPO dose per week, by modality, iron use, & data source figure 4.9 (cont.)

14. Trends in mean hemoglobin, by modality, age, gender, & race/ethnicity figure 4.10, period prevalent dialysis patients

15. Trends in mean EPO dose per week, by modality, age, gender, & race/ethnicity figure 4.11, period prevalent dialysis patients

16. Trends in mean hemoglobin, by modality, age, gender, & race/ethnicity figure 4.10, period prevalent dialysis patients

17. Trends in mean hemoglobin, by modality, age, gender, & race/ethnicity figure 4.10, period prevalent dialysis patients (cont.)

18. Trends in mean EPO dose per week, by modality, age, gender, & race/ethnicity figure 4.11, period prevalent dialysis patients

19. Trends in mean EPO dose per week, by modality, age, gender, & race/ethnicity figure 4.11, period prevalent dialysis patients (cont.)

20. Trends in patient distribution, by mean monthly hemoglobin figure 4
Trends in patient distribution, by mean monthly hemoglobin figure 4.12, period prevalent dialysis patients
100
13+
12.5-<13 80
12-<12.5 s t 60 en ti a
11-<12 p f o t 40 en rc e P
10-<11 20
<10
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001

21. Trends in patient distribution, by rolling three-month mean hemoglobin figure 4.13, period prevalent dialysis patients
100
13+
12.5-<13 80
12-<12.5 s t 60
11-<12 en ti a p f o t en 40 rc e P 20
10-<11
<10
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001

22. Trends in mean monthly hemoglobin & mean EPO dose per week figure 4
Trends in mean monthly hemoglobin & mean EPO dose per week figure 4.14, period prevalent dialysis patients

23. Mean hemoglobin: hemodialysis figure 4
Mean hemoglobin: hemodialysis figure 4.15, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(11.87)
11.57 to <11.69
11.45 to <11.57
11.30 to <11.45
below (11.11)

24. Mean EPO dose: hemodialysis figure 4
Mean EPO dose: hemodialysis figure 4.16, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean weekly EPO dose
17,030+ (19,707)
15,270 to <17,030
13,880 to <15,270
12,120 to <13,880
below 12,120 (9,976)

25. Mean hemoglobin, all-cause infections: no infections figure 4
Mean hemoglobin, all-cause infections: no infections figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.00)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (11.10)

26. Mean hemoglobin, all-cause infections: 1-2 infections figure 4
Mean hemoglobin, all-cause infections: 1-2 infections figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.04)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (11.04)

27. Mean hemoglobin, all-cause infections: 2-3 infections figure 4
Mean hemoglobin, all-cause infections: 2-3 infections figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.08)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (10.97)

28. Mean hemoglobin, all-cause infections: 3-5 infections figure 4
Mean hemoglobin, all-cause infections: 3-5 infections figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.20)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (10.79)

29. Mean hemoglobin, all-cause infections: 5+ infections figure 4
Mean hemoglobin, all-cause infections: 5+ infections figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.34)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (10.53)

30. Mean hemoglobin, all-cause infections: at least 1 infection figure 4
Mean hemoglobin, all-cause infections: at least 1 infection figure 4.17, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean hemoglobin
(g/dl)
(12.10)
11.64 to <11.79
11.52 to <11.64
11.36 to <11.52
below (11.02)

31. Mean weekly EPO dose, all-cause infections: no infections figure 4
Mean weekly EPO dose, all-cause infections: no infections figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (19,026)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (9,402)

32. Mean weekly EPO dose, all-cause infections: 1-2 infections figure 4
Mean weekly EPO dose, all-cause infections: 1-2 infections figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (20,759)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (8,305)

33. Mean weekly EPO dose, all-cause infections: 2-3 infections figure 4
Mean weekly EPO dose, all-cause infections: 2-3 infections figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (21,947)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (8,044)

34. Mean weekly EPO dose, all-cause infections: 3-5 infections figure 4
Mean weekly EPO dose, all-cause infections: 3-5 infections figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (22,375)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (8,144)

35. Mean weekly EPO dose, all-cause infections: 5+ infections figure 4
Mean weekly EPO dose, all-cause infections: 5+ infections figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (22,235)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (7,891)

36. Mean weekly EPO dose, all-cause infections: at least 1 infection figure 4.18, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Mean EPO dose
16,330+ (20,287)
14,590 to <16,330
13,250 to <14,590
11,550 to <13,250
below 11,550 (8,542)

37. Mean hemoglobin & mean EPO dose per week: all-cause infections figure 4.19, period prevalent hemodialysis patients age 20+, 2000

38. Mean hemoglobin & mean EPO dose per week: all-cause infections figure 4.19, period prevalent hemodialysis patients age 20+, 2000 (cont.)
Number of inpatient hospital stays, per patient year at risk, with infection as the principal diagnosis
All · All patients, regardless of status
1+ · Patients with at least one stay during year
A · Patients with no stays
B · Patients with 1–<2 stays
C · Patients with 2–<3 stays
D · Patients with 3–<5 stays
E · Patients with five or more stays

39. Mean hemoglobin & mean EPO dose per week: catheter infections figure 4
Mean hemoglobin & mean EPO dose per week: catheter infections figure 4.20, period prevalent hemodialysis patients age 20+, 2000

40. Mean hemoglobin & mean EPO dose per week: catheter infections figure 4
Mean hemoglobin & mean EPO dose per week: catheter infections figure 4.20, period prevalent hemodialysis patients age 20+, 2000 (cont.)
Number of inpatient hospital stays, per patient year at risk, with infection as the principal diagnosis
All · All patients, regardless of status
1+ · Patients with at least one stay during year
A · Patients with no stays
B · Patients with 1–<2 stays
C · Patients with 2–<3 stays
D · Patients with 3–<5 stays
E · Patients with five or more stays

41. Mean hemoglobin & mean EPO dose per week: catheter insertions figure 4
Mean hemoglobin & mean EPO dose per week: catheter insertions figure 4.21, period prevalent hemodialysis patients age 20+, 2000

42. Mean hemoglobin & mean EPO dose per week: catheter insertions figure 4
Mean hemoglobin & mean EPO dose per week: catheter insertions figure 4.21, period prevalent hemodialysis patients age 20+, 2000 (cont.)
Number of catheter (temporary & permanent) insertions per patient year
All · All patients, regardless of status
1+ · Patients with at least one insertion during year
a · Patients with no insertions
b · Patients with 1 insertion
c · Patients with >1–2 insertions
d · Patients with >2–3 insertions
e · Patients with three or more insertions

43. Distribution of median URR, by data source figure 4.22

44. Distribution of median URR, by gender (claims data) figure 4
Distribution of median URR, by gender (claims data) figure 4.23, period prevalent hemodialysis patients

45. Geographic variations in the % of patients meeting the K/DOQI target URR of 65%: 1998 figure 4.24, period prevalent hemodialysis patients, by HSA, unadjusted
Percent of patients
87.1+ (89.2)
86.1 to <87.1
85.3 to <86.1
84.0 to <85.3
below 84.0 (81.1)

46. Geographic variations in the % of patients meeting the K/DOQI target URR of 65%: 1999 figure 4.24, period prevalent hemodialysis patients, by HSA, unadjusted
Percent of patients
87.1+ (89.0)
86.1 to <87.1
85.3 to <86.1
84.0 to <85.3
below 84.0 (82.7)

47. Geographic variations in the % of patients meeting the K/DOQI target URR of 65%: 2000 figure 4.24, period prevalent hemodialysis patients, by HSA, unadjusted
Percent of patients
87.1+ (88.8)
86.1 to <87.1
85.3 to <86.1
84.0 to <85.3
below 84.0 (83.3)

48. Geographic variations in the % of pts meeting the K/DOQI target URR of 65%: % change, figure 4.24, period prevalent hemodialysis patients, by HSA, unadjusted
Percent change,
7.45+ (9.98)
5.76 to <7.45
4.22 to <5.76
2.52 to <4.22
below 2.52 (1.24)

49. Median URR, by unit characteristics: hemodialysis patients figure 4
Median URR, by unit characteristics: hemodialysis patients figure 4.25, period prevalent hemodialysis patients, claims data, 2000

50. Trends in mean weekly Kt/V, by unit characteristics: peritoneal dialysis patients figure 4.26, CPM data

51. Trends in mean weekly creatinine clearance, by unit characteristics: peritoneal dialysis patients figure 4.27, CPM data

52. Trends in access use, by data source figure 4
Trends in access use, by data source figure 4.28, hemodialysis patients

53. Access insertions, by unit characteristics figure 4
Access insertions, by unit characteristics figure 4.29, hemodialysis patients, 2000, CDC data

54. Insertion rates for temporary & permanent central catheters, & creation rates for simple fistulas figure 4.30, period prevalent hemodialysis patients

55. Trends in vascular access event rates, by event type figure 4
Trends in vascular access event rates, by event type figure 4.31, period prevalent hemodialysis patients

56. Trends in vascular access event rates, by event type figure 4
Trends in vascular access event rates, by event type figure 4.31, period prevalent hemodialysis patients (cont.)

57. Vascular access event rates, by MD specialty figure 4
Vascular access event rates, by MD specialty figure 4.32, period prevalent hemodialysis patients

58. Geographic variations in temporary catheter insertion rates figure 4
Geographic variations in temporary catheter insertion rates figure 4.33, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Rate per 1,000
patient years at risk
403+ (535)
298 to <403
225 to <298
165 to <225
below 165 (132)

59. Geographic variations in permanent catheter insertion rates figure 4
Geographic variations in permanent catheter insertion rates figure 4.33, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Rate per 1,000
patient years at risk
302+ (386)
237 to <302
193 to <237
150 to <193
below 150 (121)

60. Geographic variations in simple fistula creation rates figure 4
Geographic variations in simple fistula creation rates figure 4.33, period prevalent hemodialysis patients, 2000, by HSA, unadjusted
Rate per 1,000
patient years at risk
94.0+ (119.3)
78.5 to <94.0
66.0 to <78.5
53.9 to <66.0
below 53.9 (44.2)

61. Patient distribution, by hemoglobin & weekly EPO dose: IgA nephropathy/Berger’s, IgM nephropathy figure 4.34, period prevalent dialysis patients, combined

62. Patient distribution, by iron vials & weekly EPO dose: IgA nephropathy/Berger’s, IgM nephropathy figure 4.35, period prevalent dialysis patients, combined

63. Patient distribution, by hemoglobin & weekly EPO dose: Goodpasture’s syndrome figure 4.36, period prevalent dialysis patients, combined

64. Patient distribution, by iron vials & weekly EPO dose: Goodpasture’s syndrome figure 4.37, period prevalent dialysis patients, combined

65. Patient distribution, by hemoglobin & weekly EPO dose: lupus erythematosus figure 4.38, period prevalent dialysis patients, combined

66. Patient distribution, by iron vials & weekly EPO dose: lupus erythematosus figure 4.39, period prevalent dialysis patients, combined

67. Patient distribution, by hemoglobin & weekly EPO dose: other secondary GN/vasculitis figure 4.40, period prevalent dialysis patients, combined

68. Patient distribution, by iron vials & weekly EPO dose: other secondary GN/vasculitis figure 4.41, period prevalent dialysis patients, combined

69. Patient distribution, by hemoglobin & weekly EPO dose: scleroderma figure 4.42, period prevalent dialysis patients, combined

70. Patient distribution, by iron vials & weekly EPO dose: scleroderma figure 4.43, period prevalent dialysis patients, combined

71. Patient distribution, by hemoglobin & weekly EPO dose: Alport’s, other hereditary figure 4.44, period prevalent dialysis patients, combined

72. Patient distribution, by iron vials & weekly EPO dose: Alport’s, other hereditary figure 4.45, period prevalent dialysis patients, combined

73. Patient distribution, by hemoglobin & weekly EPO dose: multiple myeloma, light chain nephropathy figure 4.46, period prevalent dialysis patients, combined

74. Patient distribution, by iron vials & weekly EPO dose: multiple myeloma, light chain nephropathy figure 4.47, period prevalent dialysis patients, combined

75. Patient distribution, by hemoglobin & weekly EPO dose: AIDS figure 4
Patient distribution, by hemoglobin & weekly EPO dose: AIDS figure 4.48, period prevalent dialysis patients, combined

76. Patient distribution, by iron vials & weekly EPO dose: AIDS figure 4
Patient distribution, by iron vials & weekly EPO dose: AIDS figure 4.49, period prevalent dialysis patients, combined )